Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	**Study design**	**Risk of bias**	**Inconsistency**	**Indirectness**	**Imprecision**	**Other considerations**	**Comparison 1b: donepezil**	**placebo**	**Relative (95% CI)**	**Absolute (95% CI)**		
Cognitive abilities (follow up: 24 weeks; assessed with: Severe Impairment Battery)												
1	randomised trials	not serious	not serious	not serious	serious [1]	none	14	-	-	SMD **0.93 higher** (0.13 higher to 1.73 higher)	⊕⊕⊕◯ MODERATE	CRITICAL
Proportion with improved impression of quality of life (follow up: 24 weeks)												
1	randomised trials	not serious	not serious	not serious	serious [1]	none	11/11 (100.0%)	4/10 (40.0%)	RR 2.34 (1.14 to 4.81)	**536 more per 1000** (from 56 more to 1000 more)	⊕⊕⊕◯ MODERATE	CRITICAL
Community participation and meaningful occupation – not reported												
-	-	-	-	-	-	-					-	CRITICAL
Behavioural problems (follow up: 24 weeks; assessed with: American Association of Mental Retardation Adaptive Behaviour Scale)												
1	randomised trials	not serious	not serious	not serious	serious [1]	none	14	-	-	SMD **0.99 higher** (0.18 higher to 1.79 higher)	⊕⊕⊕◯ MODERATE	IMPORTANT
Serious adverse events (follow up: 24 weeks)												
1	randomised trials	not serious	not serious	not serious	serious [1]	none	8/16 (50.0%)	3/14 (21.4%)	RR 2.33 (0.76 to 7.13)	**285 more per 1000** (from 51 fewer to 1000 more)	⊕⊕⊕◯ MODERATE	IMPORTANT
At least one serious event (follow up: 24 weeks)												

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Comparison 1b: donepezil	placebo	Relative (95% CI)	Absolute (95% CI)		
1	randomised trials	not serious	not serious	not serious	serious [1]	none	12/16 (75.0%)	7/14 (50.0%)	RR 1.50 (0.83 to 2.72)	**250 more per 1000** (from 85 fewer to 860 more)	⨁⨁⨁◯ MODERATE	IMPORTANT
Minor adverse reaction (follow up: 24 weeks)												
1	randomised trials [2]	not serious	not serious	not serious	very serious [3]	none	2/11 (18.2%)	3/10 (30.0%)	RR 0.61 (0.13 to 2.92)	**117 fewer per 1000** (from 261 fewer to 576 more)	⨁⨁◯◯ LOW	IMPORTANT

1. Downgraded one level for imprecision (wide confidence interval). This was the criterion used in the Livingstone 2015 review.
2. Included soft stool and skin rash (donepezil, one placebo) or mild skin rash only (2 placebo).
3. Downgraded two levels for serious imprecision (wide confidence interval).